Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 2

Association of MMP9 serum levels with treatment response.

Serum MMP9	CR+PR; Median (25-75%) (ng/ml)	SD+PD; Median (25-75%) (ng/ml)	OR (95% CI)		OR (95% CI) adj	adj
Before treatment	757.4 (546.1-1175.5)	683.5 (483.4-1242.3)	1.014 (0.938-1.095)	0.728	1.032 (0.951-1.118)	0.452
After treatment	449.3 (226.4-763.3)	440.5 (269.2-640.3)	1.036 (0.925-1.160)	0.542	1.092 (0.983-1.236)	0.164
Change after treatment	-299.4 (-603.1 to -8.5)	-286.3 (-648.5 to -74.2)	1.012 (0.925-1.107)	0.797	1.020 (0.925-1.124)	0.696

Odds ratios (ORs) calculated for an increase of MMP9 levels for 100 ng/ml. Adj: adjusted for C-reactive protein; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease.